Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
Top

25-01-2021 | COVID-19 | Podcast | Article

Repurposing rheumatology drugs for COVID-19: JAK inhibitors

print
PRINT
insite
SEARCH

Speaker: Marwan Bukhari

In this series of podcasts we are speaking to the experts about repurposing rheumatology drugs for the treatment and prevention of COVID-19. 

In this episode, we discuss JAK inhibitors with Marwan Bukhari, a rheumatologist from the University Hospitals of Morecambe Bay NHS Trust in the UK. He outlines the rationale for investigating these agents, the currently available efficacy data, and the aims of the ongoing TACTIC-R trial.

Listen below or subscribe to this Podcast on:

Google Podcasts | Apple Podcasts | Spotify | Stitcher | TuneIn

About the speaker

Marwan Bukhari

Marwan Bukhari MBBS, MSc, FRCP, PhD, MAcadMEd is a consultant rheumatologist at the University Hospitals of Morecambe Bay NHS Trust and an honorary senior lecturer at Manchester University.


Full biography

print
PRINT

Repurposing rheumatology drugs for COVID-19

Experts discuss the rationale, data on different agents, and the potential impact on rheumatology practice.
  • » Featuring insights from the COVID-19 Global Rheumatology Alliance, EULAR, and the Lupus Foundation of America
Image Credits